Fujiwara, A.; Hoshino, T.; Westley, J. W. (1985). “Anthracycline Antibiotics”. Critical Reviews in Biotechnology3 (2): 133. doi:10.3109/07388558509150782.
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (June 2004). “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity”. Pharmacol. Rev.56 (2): 185–229. doi:10.1124/pr.56.2.6. PMID15169927.
Peng X, Chen B, Lim CC, Sawyer DB (June 2005). “The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine”. Mol. Interv.5 (3): 163–71. doi:10.1124/mi.5.3.6. PMID15994456.
Jensen PB, Sørensen BS, Sehested M, Demant EJ, Kjeldsen E, Friche E, Hansen HH (1993). “. Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance”. Biochem. Pharmacol.45 (10): 2025-2035. doi:10.1016/0006-2952(93)90013-M. PMID8390259.
nih.gov
pubmed.ncbi.nlm.nih.gov
Weiss RB (December 1992). “The anthracyclines: will we ever find a better doxorubicin?”. Semin. Oncol.19 (6): 670–86. PMID1462166.
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (June 2004). “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity”. Pharmacol. Rev.56 (2): 185–229. doi:10.1124/pr.56.2.6. PMID15169927.
Peng X, Chen B, Lim CC, Sawyer DB (June 2005). “The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine”. Mol. Interv.5 (3): 163–71. doi:10.1124/mi.5.3.6. PMID15994456.
Osheroff Neil (1986). “Eukaryotic Topoisomerase II: characterisation of enzyme turnover”. J. Biol. Chem.261 (21): 9944-9950. PMID3015913.
Jensen PB, Sørensen BS, Sehested M, Demant EJ, Kjeldsen E, Friche E, Hansen HH (1993). “. Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance”. Biochem. Pharmacol.45 (10): 2025-2035. doi:10.1016/0006-2952(93)90013-M. PMID8390259.